Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Accumulated Expenses (2016 - 2025)

Guided Therapeutics (GTHP) has disclosed Accumulated Expenses for 16 consecutive years, with $9000.0 as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses fell 99.11% to $9000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9000.0 through Dec 2025, down 99.11% year-over-year, with the annual reading at $9000.0 for FY2025, 99.11% down from the prior year.
  • Accumulated Expenses hit $9000.0 in Q4 2025 for Guided Therapeutics, up from $8000.0 in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $4.9 million in Q1 2021 to a low of $7000.0 in Q3 2023.
  • Historically, Accumulated Expenses has averaged $715047.2 across 5 years, with a median of $414500.0 in 2021.
  • Biggest five-year swings in Accumulated Expenses: plummeted 99.34% in 2023 and later soared 10400.0% in 2024.
  • Year by year, Accumulated Expenses stood at $49000.0 in 2021, then soared by 2444.9% to $1.2 million in 2022, then dropped by 14.35% to $1.1 million in 2023, then fell by 5.34% to $1.0 million in 2024, then tumbled by 99.11% to $9000.0 in 2025.
  • Business Quant data shows Accumulated Expenses for GTHP at $9000.0 in Q4 2025, $8000.0 in Q3 2025, and $8000.0 in Q2 2025.